drugset / Trial / NCT02458690

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690

RandomizedParallel-groupSingle-blindPrevention

Summary

The objective of this randomized controlled trial is to evaluate whether the investigators modernized IMPACT intervention for depression (eIMPACT), delivered before the onset of cardiovascular disease (CVD), reduces the risk of future CVD. Participants will be primary care patients who are depressed but do not have a history of CVD. Half of the participants will receive standard depression treatment in primary care (usual care), and the other half will receive one year of eIMPACT, a collaborative stepped care program including antidepressants and computerized and telephonic cognitive-behavioral therapy. To evaluate change in CVD risk, the investigators will measure artery function using ultrasound before and after the 1-year treatment period. It is hypothesized that patients who receive the eIMPACT intervention will have greater improvements in artery function than patients who receive usual care.

Timeline

Start
2015-07
Primary completion
2019-08
Completion
2021-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule
Subject Citalopram Small molecule
Subject Duloxetine Small molecule
Subject Escitalopram Small molecule
Subject Fluoxetine Small molecule
Subject Mirtazapine Other / unclassified
Subject Paroxetine Small molecule
Subject Sertraline Small molecule